The RSA track to include drugs for chronic diseases, asthma
By Lee, Tak-Sun | translator Kim, Jung-Ju
24.03.06 16:40:37
가나다라
0
On the 7th, the Drug Reimbursement Evaluation Committee (DREC) will devise detailed guidelines, the first case for incentivizing new drugs with innovative values
Although previously limited to anticancer and orphan drugs, Dupixent and Nucala will receive exceptions on the RSA track
The Risk Sharing Agreement (RSA) will cover chronic and severe diseases that cannot be treated with substitute drugs and result in irreversible deterioration in the quality of life.
It was announced last year as part of ‘The drug pricing system to ensure fair-value compensation for innovative new drugs.’
Since the announcement, the RSA has covered several drugs to treat chronic and severe disorders. The committee will now develop detailed guidelines to ensure the implementation of these measures.
The Drug Reimbursement Evaluation Committee (DREC) of the Health Insurance Review and Assessment Service (HIRA) will hold a meeting on the 7th to review the guidelines,
Lee, Tak-Sun(hooggasi2@dailypharm.com)
If you want to see the full article, please JOIN US (click)